Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: hepalatide, myrcludex b, bulevirtide | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 235 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13885
Sealed predictions
- SLC10A1 in dopamine neurons, braak+0.44 (p 0.234) → -0.29 (p 0.457)receipt 13892
Swarm cases
receipt 13892: SLC10A1 in dopamine neurons, braak
- power
- full sample +0.05 (p 0.840, n 18), 95% CI -0.43 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.854, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.814, n 18). could be the mix.
- skeptic
- leave-one-out range -0.07 to +0.16, sign flips 4; without severely affected donors +0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC10A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts